CCCC biotech catalysts & pipeline

C4 THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

cemsidomide — Interim data

2H 2026

• 2H 2026: Provide an update on the dose escalation progress from the Phase 1b trial evaluating the combination of cemsidomide, dexamethasone, and elranatamab.

Source filing

cemsidomide — Full data

mid-2027

C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.

Source filing

cemsidomide — Topline data

2H 2027

2H 2027: Phase 2 initial ORR data

Source filing

cemsidomide — Full data

mid-2028

• In mid-2028, present efficacy and safety for the MOMENTUM trial.

Source filing

cemsidomide — NDA/BLA submission

Late 2028

• By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later.

Source filing

cemsidomide — Conference presentation

Sep 23–Sep 26

The meeting will take place September 23–26, 2026, in Glasgow, Scotland.

Source filing

Explore the free biotech catalyst calendar